209 related articles for article (PubMed ID: 20491691)
1. Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage.
Thaler S; Fiedorowicz M; Choragiewicz TJ; Bolz S; Tura A; Henke-Fahle S; Yoeruek E; Zrenner E; Bartz-Schmidt KU; Ziemssen F; Schuettauf F
Acta Ophthalmol; 2010 Aug; 88(5):e170-6. PubMed ID: 20491691
[TBL] [Abstract][Full Text] [Related]
2. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits.
Avci B; Avci R; Inan UU; Kaderli B
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3438-46. PubMed ID: 19255151
[TBL] [Abstract][Full Text] [Related]
4. Effect of anti-VEGF antibody on retinal ganglion cells in rats.
Iriyama A; Chen YN; Tamaki Y; Yanagi Y
Br J Ophthalmol; 2007 Sep; 91(9):1230-3. PubMed ID: 17475701
[TBL] [Abstract][Full Text] [Related]
5. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
6. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy.
Horsley MB; Mandava N; Maycotte MA; Kahook MY
Am J Ophthalmol; 2010 Oct; 150(4):558-561.e1. PubMed ID: 20643396
[TBL] [Abstract][Full Text] [Related]
7. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
[TBL] [Abstract][Full Text] [Related]
8. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
[TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells.
Brar VS; Sharma RK; Murthy RK; Chalam KV
J Ocul Pharmacol Ther; 2009 Dec; 25(6):507-11. PubMed ID: 20028259
[TBL] [Abstract][Full Text] [Related]
11. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F; Adelman RA
Graefes Arch Clin Exp Ophthalmol; 2009 Feb; 247(2):171-7. PubMed ID: 18781316
[TBL] [Abstract][Full Text] [Related]
12. Toxicity assessment of intravitreal triamcinolone and bevacizumab in a retinal explant mouse model using two-photon microscopy.
Schlichtenbrede FC; Mittmann W; Rensch F; Vom Hagen F; Jonas JB; Euler T
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5880-7. PubMed ID: 19578025
[TBL] [Abstract][Full Text] [Related]
13. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
14. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
[TBL] [Abstract][Full Text] [Related]
15. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Frenkel MP; Haji SA; Frenkel RE
Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
[TBL] [Abstract][Full Text] [Related]
16. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
[TBL] [Abstract][Full Text] [Related]
17. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.
Inan UU; Avci B; Kusbeci T; Kaderli B; Avci R; Temel SG
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1773-81. PubMed ID: 17389511
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
19. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
[TBL] [Abstract][Full Text] [Related]
20. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
